Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 256

1.

The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation.

Wolchok JD, Saenger Y.

Oncologist. 2008;13 Suppl 4:2-9. doi: 10.1634/theoncologist.13-S4-2. Review.

2.

CTLA-4: negative regulator of the immune response and a target for cancer therapy.

Keilholz U.

J Immunother. 2008 Jun;31(5):431-9. doi: 10.1097/CJI.0b013e318174a4fe. Review.

PMID:
18463542
3.

Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy.

Peggs KS, Quezada SA, Allison JP.

Immunol Rev. 2008 Aug;224:141-65. doi: 10.1111/j.1600-065X.2008.00649.x. Review.

PMID:
18759925
4.

Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade.

Weber J.

Semin Oncol. 2010 Oct;37(5):430-9. doi: 10.1053/j.seminoncol.2010.09.005. Review.

PMID:
21074057
5.
6.

Cytotoxic T-lymphocyte-associated antigen-4.

Hodi FS.

Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5238-42. Review.

7.

Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanoma.

Reuben JM, Lee BN, Li C, Gomez-Navarro J, Bozon VA, Parker CA, Hernandez IM, Gutierrez C, Lopez-Berestein G, Camacho LH.

Cancer. 2006 Jun 1;106(11):2437-44.

8.
9.

Treatment and side effect management of CTLA-4 antibody therapy in metastatic melanoma.

Kähler KC, Hauschild A.

J Dtsch Dermatol Ges. 2011 Apr;9(4):277-86. doi: 10.1111/j.1610-0387.2010.07568.x. Epub 2010 Nov 17. Review. English, German.

PMID:
21083648
10.

Ctla-4 blockade confers lymphocyte resistance to regulatory T-cells in advanced melanoma: surrogate marker of efficacy of tremelimumab?

Ménard C, Ghiringhelli F, Roux S, Chaput N, Mateus C, Grohmann U, Caillat-Zucman S, Zitvogel L, Robert C.

Clin Cancer Res. 2008 Aug 15;14(16):5242-9. doi: 10.1158/1078-0432.CCR-07-4797.

11.

Role of anti-CTLA-4 therapies in the treatment of cancer.

Abrams SI.

Curr Opin Mol Ther. 2004 Feb;6(1):71-7. Review.

PMID:
15011783
12.

Cytotoxic T-lymphocyte-associated antigen-4.

Salama AK, Hodi FS.

Clin Cancer Res. 2011 Jul 15;17(14):4622-8. doi: 10.1158/1078-0432.CCR-10-2232. Epub 2011 Apr 5.

13.

[The immunotherapy potential of agonistic anti-CD137 (4-1BB) monoclonal antibodies for malignancies and chronic viral diseases].

Alfaro C, Murillo O, Tirapu I, Azpilicueta A, Huarte E, Arina A, Arribillaga L, Pérez-Gracia JL, Bendandi M, Prieto J, Lasarte JJ, Melero I.

An Sist Sanit Navar. 2006 Jan-Apr;29(1):77-96. Review. Spanish.

14.

Immunotherapy targeting 4-1BB and its ligand.

Vinay DS, Kwon BS.

Int J Hematol. 2006 Jan;83(1):23-8.

PMID:
16443548
15.

Inhibition of T cell proliferation by cholera toxin involves the modulation of costimulatory molecules CTLA-4 and CD28.

Vendetti S, Riccomi A, Sacchi A, Sciaraffia E, Gatta L, Pioli C, De Magistris MT.

Immunol Lett. 2008 Jan 15;115(1):59-69. Epub 2007 Nov 5.

PMID:
18031829
16.

Synergistic antitumor effect of chemotactic-prostate tumor-associated antigen gene-modified tumor cell vaccine and anti-CTLA-4 mAb in murine tumor model.

Li N, Qin H, Li X, Zhou C, Wang D, Ma W, Lin C, Zhang Y, Wang S, Zhang S.

Immunol Lett. 2007 Nov 15;113(2):90-8. Epub 2007 Aug 29.

PMID:
17913245
17.

Involvement of CTLA-4 in T-cell anergy induced by staphylococcal enterotoxin A in vitro.

Xu GL, Zhu XH, Guo B, Wu YZ.

Mol Immunol. 2004 May;41(1):1-8.

PMID:
15140570
18.

CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit.

Yuan J, Gnjatic S, Li H, Powel S, Gallardo HF, Ritter E, Ku GY, Jungbluth AA, Segal NH, Rasalan TS, Manukian G, Xu Y, Roman RA, Terzulli SL, Heywood M, Pogoriler E, Ritter G, Old LJ, Allison JP, Wolchok JD.

Proc Natl Acad Sci U S A. 2008 Dec 23;105(51):20410-5. doi: 10.1073/pnas.0810114105. Epub 2008 Dec 12.

19.

Overcoming immunological tolerance to melanoma: Targeting CTLA-4.

Hodi FS.

Asia Pac J Clin Oncol. 2010 Mar;6 Suppl 1:S16-23. doi: 10.1111/j.1743-7563.2010.01271.x. Review.

PMID:
20482528
20.

Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.

Ribas A, Camacho LH, Lopez-Berestein G, Pavlov D, Bulanhagui CA, Millham R, Comin-Anduix B, Reuben JM, Seja E, Parker CA, Sharma A, Glaspy JA, Gomez-Navarro J.

J Clin Oncol. 2005 Dec 10;23(35):8968-77. Epub 2005 Oct 3.

PMID:
16204013

Supplemental Content

Support Center